Metrics to compare | CTS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTSPeersSector | |
|---|---|---|---|---|
P/E Ratio | - | −3.9x | −0.3x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price/Book | 23.4x | 3.3x | 2.6x | |
Price / LTM Sales | - | 4.3x | 3.1x | |
Upside (Analyst Target) | - | 100.4% | 50.4% | |
Fair Value Upside | Unlock | 6.5% | 6.4% | Unlock |
Ceretas Limited engages in developing a portable and non-invasive therapeutic ultrasound platform for the treatment of Alzheimer's disease and other neurodegenerative conditions in Australia. The company offers a device that uses focused ultrasound beams directed through the skull to interact non-invasively with brain tissue. The company’s technology operates through two primary mechanisms, including neuromodulation, which uses low-intensity focused ultrasound to stimulate neural circuits; and BBBO, which temporarily and reversibly opens the blood-brain barrier using ultrasound combined with circulating microbubbles that facilitates brain's natural clearance of amyloid-beta and tau and helps delivery of co-administered drugs to targeted brain regions. The company was incorporated in 2024 and is based in Brisbane, Australia.